DNV Capital
Overview
DNV Capital is an international venture capital firm that focuses on early to growth stage investments in the healthcare and innovative technology industries, including medical devices, AI, IoT, and robotics.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Geneseeq | Feb 2017 | Series B Extension | Lead |
| Beijing Surgerii Robotics | Dec 2025 | Series D | Co-investor |
| Wuhan Binhui Biopharmaceutical Co., Ltd. | Apr 2022 | Series B Extension | Co-investor |
| HumanTouch Surgical | Sep 2019 | VC Round | Co-investor |
| Cyrano Therapeutics | Jan 2024 | Series B | Co-investor |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is DNV Capital based?
DNV Capital is headquartered in Shenzhen, China.
When was DNV Capital founded?
DNV Capital was founded in 2011.
How many portfolio companies does DNV Capital have?
DNV Capital has 9 portfolio companies in Caplight's dataset.
What are some companies in DNV Capital's portfolio?
Portfolio companies visible on Caplight include Geneseeq, Beijing Surgerii Robotics, Wuhan Binhui Biopharmaceutical Co., Ltd., HumanTouch Surgical, Cyrano Therapeutics.
What was DNV Capital's most recent investment shown here?
DNV Capital's most recent investment in this portfolio sample was in Beijing Surgerii Robotics in 2025.
What sectors does DNV Capital focus on?
DNV Capital focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Telecommunications & Networking, Frontier & Industrial Tech, Frontier & Industrial Tech, Frontier & Industrial Tech, Frontier & Industrial Tech, Frontier & Industrial Tech, Frontier & Industrial Tech.
What company stages does DNV Capital focus on?
DNV Capital typically invests at the Late stage.
What is DNV Capital's AUM?
DNV Capital's assets under management are estimated between $714.3M and $859.2M.